Inflammation as a risk factor for atrial fibrillation

The presence of systemic inflammation determined by elevations in C-reactive protein (CRP) has been associated with persistence of atrial fibrillation (AF). The relationship between CRP and prediction of AF has not been studied in a large population-based cohort. CRP measurement and cardiovascular a...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2003-12, Vol.108 (24), p.3006-3010
Main Authors: AVILES, Ronnier J, MARTIN, David O, CHUNG, Mina K, APPERSON-HANSEN, Carolyn, HOUGHTALING, Penny L, RAUTAHARJU, Pentti, KRONMAL, Richard A, TRACY, Russell P, VAN WAGONER, David R, PSATY, Bruce M, LAUER, Michael S
Format: Article
Language:English
Subjects:
Aged
Atrial Fibrillation - diagnosis
Atrial Fibrillation - epidemiology
Atrial Fibrillation - etiology
Biological and medical sciences
Blood and lymphatic vessels
C-Reactive Protein - analysis
Cardiology. Vascular system
Cross-Sectional Studies
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Female
Humans
Inflammation - complications
Longitudinal Studies
Male
Medical sciences
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The presence of systemic inflammation determined by elevations in C-reactive protein (CRP) has been associated with persistence of atrial fibrillation (AF). The relationship between CRP and prediction of AF has not been studied in a large population-based cohort. CRP measurement and cardiovascular assessment were performed at baseline in 5806 subjects enrolled in the Cardiovascular Health Study. Patients were followed up for a mean of 6.9+/-1.6 (median 7.8) years. AF was identified by self-reported history and ECGs at baseline and by ECGs and hospital discharge diagnoses at follow-up. Univariate and multivariate analyses were used to assess CRP as a predictor of baseline and future development of AF. At baseline, 315 subjects (5%) had AF. Compared with subjects in the first CRP quartile (3.41 mg/L) had more AF (7.4% versus 3.7%, adjusted OR 1.8, 95% CI 1.2 to 2.5; P=0.002). Of 5491 subjects without AF at baseline, 897 (16%) developed AF during follow-up. Baseline CRP predicted higher risk for developing future AF (fourth versus first quartile adjusted hazard ratio 1.31, 95% CI 1.08 to 1.58; P=0.005). When treated as a continuous variable, elevated CRP predicted increased risk for developing future AF (adjusted hazard ratio for 1-SD increase, 1.24; 95% CI 1.11 to 1.40; P
ISSN:0009-7322
1524-4539
DOI:10.1161/01.CIR.0000103131.70301.4F